User login
Cancer treatment is evolving rapidly, and 2015 was no exception. It was the year of immunotherapy. Following the approval by the US Food and Drug Administration in 2014 of pembrolizumab for melanoma, 2015 saw approvals of nivolumab for melanoma, lung cancer, and kidney cancer; pembrolizumab for lung cancer; and the combination of ipilimumab and nivolimab for melanoma. That’s an impressive list of immunotherapy approvals for a single year.
Click on the PDF icon at the top of this introduction to read the full article.
Cancer treatment is evolving rapidly, and 2015 was no exception. It was the year of immunotherapy. Following the approval by the US Food and Drug Administration in 2014 of pembrolizumab for melanoma, 2015 saw approvals of nivolumab for melanoma, lung cancer, and kidney cancer; pembrolizumab for lung cancer; and the combination of ipilimumab and nivolimab for melanoma. That’s an impressive list of immunotherapy approvals for a single year.
Click on the PDF icon at the top of this introduction to read the full article.
Cancer treatment is evolving rapidly, and 2015 was no exception. It was the year of immunotherapy. Following the approval by the US Food and Drug Administration in 2014 of pembrolizumab for melanoma, 2015 saw approvals of nivolumab for melanoma, lung cancer, and kidney cancer; pembrolizumab for lung cancer; and the combination of ipilimumab and nivolimab for melanoma. That’s an impressive list of immunotherapy approvals for a single year.
Click on the PDF icon at the top of this introduction to read the full article.